{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
penicillin v
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Eleclazine (formerly known as GS-6615) is a dihydrobenzoxazepinone selective cardiac late sodium current inhibitor. Gilead Sciences is developing eleclazine as an oral treatment for long QT syndrome, hypertrophic cardiomyopathy, ischaemic heart disease, and Ventricular arrhythmias.
Status:
Investigational
Source:
NCT01424397: Phase 2 Interventional Completed Rhinitis
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
SB-705498 is a selective vanilloid receptor-1 (VR1/TRPV1) antagonist developed by GlaxoSmithKline. The drug was tested in phase II of clinical trials for the treatment of pain (dental, rectal, in migraine) and rhinitis/cough. The development of the drug has been terminated by unknown reason (SB-705498 is no longer in GSK pipeline).
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Pocapavir is a capsid-binding molecule. It is a capsid inhibitor that blocks virus uncoating and viral RNA release into cells, which in turn prevents virus replication. Pocapavir is a potent, selective, anti-enterovirus molecule with in vitro and in vivo activities. Antiviral testing against viruses of the 15 most commonly isolated enterovirus serotypes indicates that pocapavir inhibits 80% of the immunotypes (154 viruses) at a concentration that is within the levels of the molecule achievable in plasma after oral dosing in higher animals. Persistent low viral load after therapy completion may indicate lack of antiviral effect from pocapavir for neonatal enteroviral sepsis treatment. Pocapavir had been in phase II clinical trial for the treatment of poliomyelitis but no recent reports on development were identified.
Status:
Investigational
Source:
NCT02215252: Phase 2 Interventional Completed Diabetic Neuropathy, Painful
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
PF-05089771 is an oral administrated Nav1.7 channel inhibitor. PF-05089771 provided the best opportunity to explore Nav1.7 blockade for the treatment of acute or chronic pain conditions. PF-05089771 has completed Phase II clinical trials of third molar extraction and primary inherited erythromelalgia. The magnitude of efficacy of PF-05089771 in the randomized, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy was disappointing. Although there was a trend towards a reduction in pain and improvement in sleep rating in patients with painful DPN when compared to placebo treatment, this was not statistically significant.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tetramethylhexamethylenediamine (6,3-ionene) is a Hexanediamine derivative patented by Abbott Laboratories. U.S.A. as heparin neutralizer. Heparin is anionic polymer and positively charged Tetramethylhexamethylenediamine, prevents its anticoagulant action. The antagonistic capacity would be due to the PEC formation between the ionene and heparin. Tetramethylhexamethylenediamine can also be used as an antispasmolytic drug.
Status:
Investigational
Source:
NCT01019928: Phase 2 Interventional Completed Sensitivity in Esophagus
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Suncillin is an antibacteria and antifungal agent produced in Phytera's laboratory from a cell culture of a plant. Suncillin was patented by Bristol-Myers Co. In 1968 for the Pseudomonas bacteria treatment but was never marketed.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Olvanil, a structural analog of capsaicin, is an agonist of the transient receptor potential vanilloid type-1 (TRPV1) channel. This compound was developed as a potential analgesic compound. Olvanil has potent anti-hyperalgesic effects in several experimental models of chronic pain.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Lodelaben (SC-39026) is a human neutrophil elastase inhibitor. Its inhibition of elastase is reversible and noncompetitive at low concentrations. Inhibition is "mixed" at higher inhibitor concentrations. SC-39026 is inactive against hog pancreatic elastase, bovine alpha-chymotrypsin and Pseudomonas aeruginosa elastase, but does inhibit human neutrophil cathepsin G. Lodelaben was developed as antiarthritic agent and tested as adjunct to emphysema therapy. Monocrotaline-injected rats given SC-39026 had significantly lower mean pulmonary artery pressure than those given vehicle, and this correlated with a significant reduction in the number of abnormally muscularized arteries at alveolar wall level. SC-39026 did not significantly reduce monocrotaline-induced medial hypertrophy of muscular arteries, endothelial injury, and associated subendothelial edema. Lodelaben reduces endotoxin-induced lung dysfunction in awake sheep.
